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The clinical success of the Abl kinase
inhibitor STI-571 (Gleevec/imatinib) in the
treatment of chronic myeloid leukemia
(CML) has focused renewed enthusiasm
toward understanding the pharmacology
of kinase inhibition. Virtually all the
kinase inhibitors currently in clinical test-
ing were discovered through the process
of empiric high-throughput screening of
large chemical libraries against kinase
targets rather than through rationale
design of drugs based on knowledge of
kinase domain structure. However, there
is great optimism that crystallographic
data of kinases in various states of acti-
vation will lead to structure-based drug
design. A recent article in Cell by Superti-
Furga and colleagues provides com-
pelling evidence that the c-Abl kinase is
negatively regulated by the N terminus of
the wild-type protein, which is deleted
when fused to Bcr (Pluk et al., 2002).
While this model must be confirmed by
crystallographic studies, this mode of
kinase regulation could have implica-
tions for the design of future kinase
inhibitor drugs.
Solutions of the Src and Hck struc-
tures provided the first evidence that this
family of kinases is regulated by a com-
plex set of intramolecular interactions
between the SH2, SH3, and catalytic
domains. One unanticipated finding was
that the linker region between the SH2
and catalytic domains forms a polypro-
line helix which binds the SH3 domain,
bringing it into close proximity with the
catalytic domain where it exerts an
inhibitory function (Sicheri et al., 1997;
Xu et al., 1997). Although similar struc-
tural data for Abl is not yet available, the
homology between Abl and Src kinases
as well as mutational studies suggest a
similar mode of regulation (Barila and
Superti-Furga, 1998). A critical aspect of
Src kinase regulation is an intramolecu-
lar interaction between the SH2 domain
and a phosphotyrosine residue in the C
terminus. This interaction plays a nega-
tive regulatory role, in part, by position-
ing the SH3 domain in a proper con-
figuration for inhibition of the catalytic
domain. This design permits Src regula-
tion at multiple levels—through phos-
phorylation/dephosphorylation of the C-
terminal tyrosine residue as well as
through competition between intramo-
lecular and external ligands for SH2/SH3
domain binding.
A long-standing puzzle surrounding
Abl regulation stems from the fact that its
C terminus does not contain an analo-
gous regulatory tyrosine residue that
could function to bind the Abl SH2
domain. Without this analogous struc-
ture, how could the inhibitory SH3-cat-
alytic domain interaction be maintained?
Superti-Furga and colleagues provide
strong evidence that the N terminus of c-
Abl serves this function by forming a
“cap” structure, through direct interaction
with the catalytic domain and SH2/SH3
domains (Pluk et al., 2002) (Figure 1). In
addition to providing an attractive solu-
tion to the puzzle over differences in Src
versus Abl regulation, the new data will
force a reexamination of the function of
several Abl binding proteins previously
proposed to function as cellular inhibitors
of Abl.
The Superti-Furga paper raises
some fascinating issues regarding the
biology of tyrosine kinase regulation. But
does it have implications for the treat-
ment of diseases such as CML, whose
pathogenesis is dependent on Abl
kinase activation through fusion to Bcr?
This question is of immediate interest
based on the remarkable success of the
Abl kinase inhibitor STI-571 in treating
patients with various stages of CML. STI-
571 was originally isolated in a high
throughput screen for small molecule
inhibitors of the PDGF receptor tyrosine
kinase (Buchdunger et al., 1995), and
subsequently shown to have potent
inhibitory activity against two other tyro-
sine kinases, Abl and c-Kit. The large
body of clinical and experimental evi-
dence that the Bcr-Abl fusion protein is
the initiating oncogenic event in CML
(reviewed in Sawyers, 1999) led to pre-
clinical studies showing activity of STI-
571 against Bcr-Abl expressing tumor
cell lines and bone marrow cells isolated
from patients with CML (Druker et al.,
1996). A phase I clinical trial showed a
98% hematologic response rate in CML
patients in the chronic phase of the dis-
ease and a 60%–70% hematologic
response rate in the end stage of the dis-
Disabling Abl—Perspectives on Abl kinase regulation
and cancer therapeutics
Pharmacologic inhibition of the Bcr-Abl tyrosine kinase in human chronic myeloid leukemia leads to dramatic clinical
responses, but relapses occur in advanced stage patients. New findings about Abl kinase domain regulation provide
insight into novel strategies for targeted therapy.
Figure 1. The putative structure of Abl in the
regulated, inactive conformation is shown
on the left, with the SH3 domain exerting an
inhibitory function on the catalytic domain
(CAT) by binding to the SH2-CAT linker
region. The N-terminal cap (red) locks the
SH3 domain in this configuration by binding
to it as well as the CAT domain. In the Bcr-Abl
fusion protein (right panel), the N-terminal
cap is removed and the kinase domain
remains unregulated.
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ease, termed blast crisis (Druker et al.,
2001a, 2001b). STI-571 was approved
for clinical use by the US Food and Drug
Administration in May, 2001, based on
similar results in phase II studies.
One of the remarkable surprises
from these clinical trials was the high
response rate in CML patients with blast
crisis, indicating that these tumor cells
depend on Bcr-Abl despite the pres-
ence of multiple additional oncogenic
abnormalities. Unfortunately, these pa-
tients relapse despite continued treat-
ment with STI-571. Recent investiga-
tions into mechanisms of STI-571 resis-
tance shows that Bcr-Abl signaling,
which is inhibited in leukemia cells when
patients are responding to STI-571 treat-
ment, is reactivated at the time of relapse
(Gorre et al., 2001). It seems, therefore,
that blast crisis cells rely on the Bcr-Abl
signal transduction pathway even at the
very latest stages of disease.To date, the
primary mechanisms responsible for
Bcr-Abl reactivation are kinase domain
mutations which impair binding of STI-
571 to the active site in the catalytic
domain or amplification of the Bcr-Abl
gene (Gorre et al., 2001).
Structural data of the Abl kinase
domain bound to STI-571 (Schindler et
al., 2000) has been critical to under-
standing how these mutations detected
in relapsed CML patients confer drug
resistance. The best documented exam-
ple is a threonine-to-isoleucine change
reported by several groups (Gorre et al.,
2001; summarized in Sawyers, 2001).
This threonine residue resides on the
surface of the drug binding pocket and
forms a hydrogen bond with STI-571. In
the mutant Bcr-Abl allele, the bulkier
isoleucine substitution prevents STI-571
binding due to steric hindrance at the
drug binding pocket and inability to form
the hydrogen bond. Because this threo-
nine is conserved in many tyrosine
kinases, it might be anticipated to play a
more general role in mechanisms of
kinase inhibition by other small mole-
cule inhibitors as well as in mechanisms
of potential drug resistance. Another
important insight from the Abl/STI-571
structure is a better understanding of
how certain inhibitors can show differen-
tial activity against kinases that appear
quite similar by amino acid sequence,
particularly at the ATP binding site. STI-
571 binds to Abl when the kinase domain
is in the “off” configuration (Schindler et
al., 2000), which is structurally quite dis-
tinct from the “off” configuration of Src.
This structural difference between Abl
and Src provides a compelling explana-
tion for why STI-571 shows inhibitory
activity only against Abl. On the other
hand, kinase inhibitors such as PP-1
have activity against both Src and Abl
(Liu et al., 1999), perhaps because these
compounds bind the kinases in an
“active” configuration where they are
structurally more similar.
Could the new insights about Abl
kinase regulation provided by the
Superti-Furga paper help design better
kinase inhibitors for CML? To address
this possibility, it is critical to understand
the mechanism of Abl kinase activation
in the Bcr-Abl fusion protein. The prevail-
ing model is that the coiled-coil dimeriza-
tion motif in Bcr serves as a gain-of-func-
tion mutation that leads to constitutive
Abl kinase activation. The Superti-Furga
paper raises the intriguing possibility that
the fusion protein, which lacks the
inhibitory N terminus of Abl, is activated
by a loss-of-function mechanism (Figure
1). I can envision two potential conse-
quences for clinical medicine. First, there
are many patients with CML-like hemato-
logic disorders that defy molecular clas-
sification because they lack the Bcr-Abl
fusion protein (this disease is often
called Philadelphia chromosome nega-
tive CML). Fusions of Abl or the Abl-relat-
ed protein Arg to the Ets-like protein Tel
(also called ETV6) have been reported in
rare cases (Papadopoulos et al., 1995;
Cazzaniga et al., 1999), and the mecha-
nism of Abl/Arg activation in these
fusions appears similar to Bcr-Abl since
Tel also contains a dimerization motif
(Golub et al., 1996). It will be important
to know if any cases of Philadelphia
chromosome negative CML might be
explained by N-terminal mutations that
lead to Abl activation. A second clinical
implication of the Superti-Furga model is
that regulation of Abl kinase activity
might be restored in CML by forcing the
SH2/SH3 domain and linker structure
back into a conformation that inhibits the
catalytic domain. The authors provide
some evidence that this may be possible
by showing inhibitory effects of the N-ter-
minal cap on Abl kinase activity when
provided in trans. Analogous experi-
ments with Bcr-Abl may prove more chal-
lenging, since reconstitution of the N-ter-
minal cap in cis with Bcr-Abl (through
creation of a Bcr/N-cap/Abl fusion) failed
to inhibit kinase activity unless the dimer-
ization motif in Bcr was impaired. This
result should not discourage further
investigation because it may be possible
to target Bcr independently, as the crys-
tal structure of this dimerization motif has
recently been solved (Zhao et al., 2002).
In a recent episode of the popular televi-
sion show West Wing about life in the
White House, President Bartlett consid-
ered a campaign to eliminate cancer in
ten years, based on new evidence that
signal transduction inhibitors (called STI)
can cure cancer. Hopefully this fictional
episode will one day become a nonfiction
documentary.
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The application of functional genomics to
the analysis of breast cancer samples
holds great promise in producing a sub-
stantial advance in breast cancer prog-
nostication. In a recent issue of Nature,
van’t Veer et al. describe their ability to
determine with substantial accuracy
whether a young node-negative patient
will or will not show progressive disease
within five years time (van ‘t Veer et al.,
2002).
This work highlights a painful dispar-
ity in current clinical practice: oncologists
are able to detect tumors of ever smaller
size (current avg.: 1.5 cm diameter) in
the breast, but their ability to exploit the
diagnostic parameters associated with
these relatively small tumors in order to
predict eventual outcome has lagged far
behind.
The oncologic territory has changed
dramatically over the past two decades.
With improving public awareness and
detection techniques, as many as
60%–70% of breast cancer patients cur-
rently present clinically at an early stage
while still being node-negative. That is,
the axillary lymph nodes, which drain
much of the mammary gland, are found
to be free of detectable cancer cells
through light microscopy.
Since the 10-year recurrence rate in
node-positive patients is approximately
70%, the standard practice is to adminis-
ter systemic adjuvant therapy to all
patients in this group. This therapy
involves anti-estrogen treatment (in the
case of estrogen receptor-positive
tumors), Herceptin (in the case of
HER2/neu-positive tumors), and often
cytotoxic drugs.
The treatment decision for node-
negative patients, however, is not as
straightforward. Approximately 70%–
80% of the node-negative group will sur-
vive breast cancer without additional
treatment beyond surgical resection of
the initially detected growth. Hence,
many argue that adjuvant systemic ther-
apy, which can have significant toxicities,
should not be undertaken routinely, since
one risks harming many for the benefit of
a few (Harris et al., 2000; Bland et al.,
1998).
The dramatic shift in the clinical sta-
tus of women at the time of initial presen-
tation in the clinic now creates a sub-
stantial and still-to-be-solved problem,
because many of the standard patholog-
ic prognostic factors currently used were
developed in an earlier era when a
majority of the patients presented with
larger (>2 cm diameter) tumors and were
node-positive.
Among the many studies that have
examined prognostic factors for breast
cancer, only a few have specifically
focused on node-negative patients (Mirza
et al., 2002). Moreover, standard prog-
nostic factors such as tumor size, histo-
logical type, grade of differentiation, and
hormone receptor status were found to
have limited value in predicting which
node-negative patients would relapse.
As a result, physicians have very few
tools available for determining which
node-negative patients should receive
adjuvant therapy.
The landscape has also changed in
yet another respect. Some of the tradi-
tional markers (e.g., estrogen receptor,
ER) have been useful not only to predict
outcome but also to inform therapy, since
anti-ER agents such as tamoxifen have
been available and found useful for
improving short-term survival. Now, with
the advent of novel therapies (e.g.,
Herceptin), other markers, such as
Her2/neu expression, gain in importance
because of their role in conferring
responsiveness to these newly devel-
oped agents.
This complex picture reveals the dis-
ease of breast cancer to be a rapidly
moving target, where the perceived rele-
vance of widely used diagnostic and
prognostic parameters may change dra-
matically over a period of several years.
The mysteries of breast cancer
epidemiology
The number of diagnosed breast can-
cers in the Western world has increased
substantially over the past half century.
For example, in 1990, an estimated
150,000 new cases were reported in the
United States while six years later, the
number had increased to 185,000.
During the same time period, estimated
deaths due to breast cancer remained
constant (44,000) (Harris et al., 2000).
However, there is some hope on the hori-
zon: over the past several years, age-
adjusted mortality of breast cancer has
actually declined slightly (1.7% per
Functional genomics and the breast cancer problem
The clinical treatment of primary breast cancers has been greatly complicated by the inability to accurately predict which
tumors will eventually become invasive and metastatic and which will remain localized and indolent. Lacking the ability to
discriminate between these two classes of breast cancer patients, oncologists often apply aggressive adjuvant therapy to
women in both groups. However, the use of functional genomics analysis has now made it possible to assemble a set of
gene markers, the expression of which enables one to predict, with reasonably high accuracy, whether or not the patient
will relapse or remain tumor-free five years after initial diagnosis and treatment.
